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Development of a Sensitive Phospho-p70S6Kinase ELISA to
Quantify mTOR Proliferation Signal Inhibition
Bertram Hartmann, MD,* Xuemei He, MD,† Frieder Keller, MD,* Michael Fischereder, MD,‡
Markus Guba, MD,§ and Holger Schmid, MD‡
Background: Drug blood levels can only serve as a surrogate
because of the lack of information on the drug’s direct pharma-
cological effects in the individual patient. Measurement of
the mammalian target of rapamycin (mTOR) activity dependent
on the phosphorylation status of p70 S6 kinase (p70 S6K) offers
a practical way for monitoring pharmacodynamic drug activity,
with the potential to better assess the state of immunosuppre-
ssion in individual patients.
Material and Methods: Here, we established a novel in vitro
model system by treating Jurkat cells and peripheral blood
mononuclear cells with different concentrations of sirolimus after
stimulation with phorbol 12-myristate 13-acetate.
Results: A dose-dependent reduction of the p70 S6K phosphor-
ylation status was demonstrated by Western blot and a newly
established enzyme-linked immunosorbent assay (ELISA). Rela-
tive phospho-p70 S6K values from ELISA and relative densities
from Western blot analysis in peripheral blood mononuclear cells
revealed a strong correlation (Spearman correlation coefficient rs =
0.7, P = 0.01). Finally, parallel assays confirmed a sirolimus dose-
dependent reduction of cytokine production and cell proliferation
in the in vitro model.
Conclusions: Pharmacodynamic monitoring of mTOR inhibi-
tion with a p70 S6K ELISA could guide mTOR inhibitor
immunosuppression therapy toward a more individualized ther-
apy. The usage of this technique now has to be evaluated in
a clinical series of patients.
Key Words: pharmacodynamic monitoring, immunosuppression,
mTOR inhibitor, p70 S6 kinase, sirolimus, therapeutic drug
monitoring
(Ther Drug Monit 2013;35:233–239)
INTRODUCTION
For eligible patients, kidney transplantation offers the
best method for renal replacement therapy, but unfortunately,
immunosuppressive agents, for example, calcineurin inhibitors,
failed to improve long-term outcomes.1 The proliferation
signal inhibitor rapamycin (ie, sirolimus and its derivative ever-
olimus) provides appropriate immunosuppression without
significant nephrotoxicity.2 In addition, sirolimus-based calci-
neurin inhibitor–free therapy is associated with a decreased
incidence of de novo malignancies.3 Despite such favorable
effects, maintenance mammalian target of rapamycin (mTOR)
inhibitor therapy has to be stopped in approximately 30%–50%
of patients due to related side effects.3–5 Currently, dose adjust-
ment of the mTOR inhibitors entirely relies on measurement of
their whole-blood concentration. Recommended trough levels
for sirolimus range from 5 to 15 ng/mL, but sirolimus trough
concentrations might not necessarily correlate with the biolog-
ical effects of the drug on immune cells or other tissues. Siro-
limus is extensively partitioned into solvent and formed blood
elements.6 The proportion of the drug that distributes to lym-
phocytes is only 1% of whole-blood concentration.7,8 Therefore,
small differences in drug partitioning might have a relevant
biological impact on the immune system and produce adverse
effects. P70 S6 Kinase (p70 S6K) is described as one of the best
characterized downstream effectors of mTOR activation.9
Through activation of mTOR, phospho-p70 S6K stimulates
the production of ribosomal components necessary for protein
synthesis and cell cycle progression.10 Pharmacodynamic mon-
itoring of mTOR inhibitor–based immunosuppression by
assessment of the phosphorylation status of p70 S6K might
represent an important advantage because it enables individual-
ized immunosuppression. The mTOR proliferation signal inhib-
itor forms a complex with the FK-binding protein. This
complex binds with high affinity to the mTOR and causes its
inhibition. The downstream effects of mTOR activation are
reduced and p70 S6K will be inactivated.8,11 The feasibility
of monitoring mTOR inhibitor–based immunosuppression has
been demonstrated by Western blot analysis of the phosphory-
lation status at the Thr389 site of the p70 S6K in peripheral
blood mononuclear cells (PBMCs).12,13 However, Western blot
analysis represents a semiquantitative method and is therefore
inapplicable to further large population studies and interindivid-
ual comparison. Here, we established a novel method by using
a commercial enzyme-linked immunosorbent assay (ELISA) kit
that facilitates assessment of the phosphorylation of p70 S6K in
a cell model and could enable the pharmacodynamic monitor-
ing of mTOR proliferation signal inhibition.
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MATERIAL AND METHODS
Cell Culture and Cell Treatment
Freshly isolated PBMCs and Jurkat T-leukemia cells
(German Collection of Microorganisms and Cell Cultures)
were used. Human PBMCs were isolated from buffy coats
after Ficoll density gradient centrifugation. Buffy coat
preparations of healthy donors were obtained from the
German Red Cross (Deutsches Rotes Kreuz, Germany) after
informed consent was obtained.
To increase the amount of phospho-p70 S6K and to have
it comparable to the activated immune system after trans-
plantation, we investigated different conditions: starving cells,
incubation with insulin or insulin-like growth factor, and also
unspecific stimulation with phytohemagglutinin (PHA) or
phorbol 12-myristate 13-acetate (PMA). The cells were
stimulated with 3 different concentrations of PMA (125, 250,
500 ng/mL) for different times (15, 30, 60 minutes). Best
results were achieved after stimulation with PMA (125 ng/mL,
incubation time 30 minutes).
To investigate the effect of sirolimus on phospho-p70
S6K, serial concentrations of sirolimus (0, 0.75, 1, 2, 3 nM for
Jurkat cells; 0, 0.25, 0.5, 0.75, 1 nM for PBMCs) were added
in presence or absence of PMA to the cells. The cells were
lysed after incubation at 378C in humidified air with 5% CO2
for 30 minutes. These lysates were analyzed for phospho-p70
S6K with Western blot and subsequently with ELISA.
Cell Lysis
Cells were collected by centrifugation at 420g for 10
minutes at 48C and washed with ice-cold phosphate-buffered
saline once. Cells (2.5 · 107 Jurkat cells or 108 PBMCs) were
lysed by incubation with 1 mL of cell extraction buffer [10 mM
Tris pH 7.4, 100 mM NaCl, 1 mM EDTA (ethylenediaminete-
traacetic acid), 1 mM EGTA (ethylene glycol tetraacetic acid),
1 mMNaF, 20 mMNa4P2O7, 2 mMNa3VO4, 1% Triton X-100,
10% glycerol, 0.1% SDS (sodium dodecyl sulfate), 0.5% deox-
ycholate] supplemented with 1 mM PMSF (Phenylmethylsulfo-
nylfluoride) and a protease inhibitor cocktail (Sigma-Aldrich) on
ice for 30 minutes. The cell lysates were clarified by centrifuga-
tion at 20,800g for 10 minutes at 48C and stored at 2808C.
Bicinchoninic Acid Protein Assay
Protein concentration was determined by bicincho-
ninic acid protein assay reagent kit (Pierce Biotechnology,
Rockford, IL) according to manufacturer’s instructions. Ten
microliters of standards and 10 mL of diluted lysates were
pipetted into a 96-well plate in triplicate. Then 200 mL
freshly prepared bicinchoninic acid working reagent was
added to each well. The plate was incubated at 378C for
30 minutes. The absorbance at 562 nm was measured on
the plate reader. The protein concentration of each sample
was determined by using the standard curve.
Western Blot
Western blot analysis was performed as previously
described.12 Briefly, equal amounts of cell lysates were mixed
with 5· sample buffer (58 mM Tris HCl/SDS, 44% glycerol,
9.8% SDS, 0.5 M 2-mercaptoethanol, 0.05% Bromophenol
blue), heated at 958C for 4 minutes. Aliquots that contained
40 mcg of protein from each lysate were subjected to 7.5%
SDS polyacrylamide gel electrophoresis with 70 V for 30
minutes and then with 100 V for 60 minutes in running buffer
(25 mM Tris, 192 mM glycine, 0.1% SDS) and then electro-
transferred into a Hybond P membrane by using 100 V for
60 minutes in transfer buffer (25 mM Tris, 192 mM glycine)
with 15% methanol. After blocking in freshly prepared Tris-
Tween–buffered saline [TTBS (0.02 M Tris, 0.1 M sodium
chloride with 0.1% Tween 20)] containing 3% nonfat dry milk
at room temperature for 1 hour, membranes were blotted over-
night at 48C with polyclonal rabbit antiphospho-p70 S6K
antibody targeted to threonine 389 (Cell Signaling) with
1:1000 dilution in 5% bovine serum albumin. Membranes were
then washed in TTBS 3 times and incubated for 1 hour with an
anti-rabbit IgG horseradish-conjugated secondary antibody
(Amersham Biosciences) at a 1:5000 dilution in TTBS contain-
ing 1% nonfat dry milk. To confirm equal loading, the same
membranes were immunoblotted with anti-b-actin mouse mono-
clonal IgG1 antibodies (Santa Cruz Biotechnology) overnight at
48C at 1:10,000 dilution in TTBS containing 1% nonfat dry
milk. Membranes were then washed in TTBS 3 times and incu-
bated for 1 hour with an anti-mouse IgG horseradish-conjugated
secondary antibody (Amersham Biosciences) at a dilution of
1:5000 in TTBS containing 1% nonfat dry milk. The bound
proteins were visualized with the enhanced chemiluminescence
system. The intensity of signals detected by exposure to Cronex
5 medical x-ray films was quantitated by densitometry analysis
(Image J software). Results were expressed by density relative to
b-actin and then normalized to basal concentrations of phospho-
p70 S6K (Thr389) or phospho-p85 S6K (Thr412) in Jurkat cells
or PBMCs.
Phospho-p70 S6K (Thr389) ELISA
Phospho-p70 S6K (Thr389) concentrations were mea-
sured with p70 S6K (Thr389) immunoassay kits (Invitrogen,
Life Technologies). This test is a solid-phase ELISA. A
monoclonal antibody specific for p70 S6K (regardless of
phosphorylation state) has been coated into the wells of the
microtiter plate. Serial dilutions of the standard (100, 50, 25,
12.5, 6.25, 3.12, 1.6, and 0 U/mL) were prepared. Five
microliters of samples were incubated with 5 mL of sample
treatment buffer on ice for 20 minutes. These mixtures were
then diluted in standard diluent buffer to obtain a protein
concentration at 0.1 mg/mL. Standard dilutions containing
phospho-p70 S6K (Thr389) and diluted lysates were pipetted
into the 96-well plate in duplicate together with a rabbit poly-
clonal (detection) antibody specific for phospho-p70 S6K
(Thr389) and incubated for 3 hours at room temperature.
After a washing procedure, the horseradish peroxidase-
labeled anti-rabbit IgG (anti-rabbit IgG-HRP) working solu-
tion was added to each well for further 30 minutes. Finally,
after another washing procedure, a substrate solution was
added to induce the color reaction. After incubation for 30
minutes in the dark, a stop solution was added to each well
and the absorbance of each well at 450 nm was measured by
a microplate reader. Results were expressed in units after
normalization to 100 mcg total protein (U/100 mcg protein).
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Proliferation Assays
Proliferation assays were performed by the CellTiter
96 AQueous One Solution Reagent (Promega) containing
a tetrazolium compound [3-(4, 5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4 sulfophenyl)-2H-tetrazo-
lium, inner salt; MTS]. MTS is bioreduced by cells into
a colored formazan product, which is soluble in tissue
culture medium. This conversion is presumably accom-
plished by nicotinamide adenine dinucleotide 20-phosphate
reduced tetrasodium salt or dihydronicotinamide adenine
dinucleotide produced by dehydrogenase enzymes in met-
abolically active cells. The quantity of formazan product as
measured by the absorbance at 490 nm is directly propor-
tional to the number of living cells in culture.
Cytokine Determinations
Supernatants were collected from Jurkat cells (0.3 · 106
cells/mL) and incubated with 3 mM ionomycin plus 5 ng/mL
PMA and different concentrations of sirolimus (0, 0.75, 1, 2,
and 3 nM) or DMSO (0.01%) at 378C in a humidified atmo-
sphere with 5% CO2 for 48 hours.
Similarly, the supernatants were collected after treatment
of PBMCs (0.6 · 106 cells/mL) with 20 mcg/mL PHA plus
125 ng/mL PMA. Serial concentrations of sirolimus (0, 0.25,
0.5, 0.75, and 1 nM) or DMSO (0.01%) were added at 378C in
humidified atmosphere with 5% CO2 for 72 hours. The cyto-
kines (IL-2, TNF, IFN-g) in the supernatants were determined
by ELISA (BD Biosciences).
Statistical Analyses
Results are presented as mean 6 SD. Statistical signifi-
cance (P , 0.05) was evaluated using 1-way analysis of
variation (phospho-p70 S6K ELISA) or paired t test (prolifer-
ation assays, cytokine determinations). Statistical significance
(P , 0.01) was evaluated using bivariate Spearman rank
correlation analysis between the relative phospho-p70 S6K
values from ELISA and logarithmically transformed relative
densities from Western blot analysis. SPSS software (version
11.5) was used for all statistical analyses. Sigmaplot (2001)
was used for semi-log scatter plot.
RESULTS
Stimulation With PMA Increased Low Basal
Concentrations of Phospho-p70 S6K
Western blot analysis detected the 2 isoforms of the S6
Kinase p70 S6K and p85 S6K. The basal concentration
of phospho-p70 S6K expression was very low. The phorbol
ester phorbol 12-myristate 13-acetate (PMA), an activator of
the mTOR pathway,14–16 was used to increase the amount of
phospho-p70 S6K. On the other hand, PBMC stimulated with
PMA might also be comparable to the activated immune sys-
tem after transplantation. Obvious phosphorylation of p70 S6K
was achieved 15–30 minutes after stimulation with different
concentrations of PMA in PBMCs. In the following experi-
ments, 125 ng/mL of PMA was added to cells and incubated
for 30 minutes. Interestingly, PMA prompted only a weak
phosphorylation of p86 SK6 (Fig. 1).
Sirolimus Induced a Dose-dependent
Depression of p70 S6K Phosphorylation in
PMA-stimulated PBMCs
Cells were incubated with different concentrations of
sirolimus (0–1 nM) together with PMA (125 ng/mL) stim-
ulation for 30 minutes. In Western blot analysis (Fig. 2A),
the phospho-S6K1 phosphorylation was measured at
Thr389 (p70 S6K) and Thr412 (p85 S6K) as previously
described.16 In PMA-stimulated PBMCs, sirolimus pre-
vented phosphorylation of p70 S6K in a dose-dependent
manner (Fig. 2B). A PMA-induced increase in phospho-
S6K1 was dose-dependently downregulated by sirolimus,
although the extent of downregulation was lower than that
of phospho-p70 S6K. In contrast, the PMA-induced slight
increase in phospho-p85 S6K did not show a significant
downregulation by sirolimus. In PMA-stimulated cells,
the downregulating effect of sirolimus on the elevated con-
centrations of phospho-S6K1 was similar to that on phos-
pho-p70 S6K.
Contrary to the results in PMA-stimulated cells, in
unstimulated cells, the phospho-p85 S6K band was stronger
than the phospho-p70 S6K band, suggesting that in unsti-
mulated cells phospho-p85 S6K contributed much more to the
concentrations of phospho-S6K1 than phospho-p70 S6K.
Densitometry analysis of Western blots from 20 buffy coats
(Fig. 2C) demonstrated the same tendency as that from the
representative buffy coat (Fig. 2B).
Parallel Measurements of Cell Proliferation
and Distinct Cytokine Production Confirmed
Efficacy of Sirolimus Treatment
To analyze whether sirolimus-induced downregulation
of phospho-p70 S6K parallels to the downregulation of the
cellular immune functions, MTS proliferation assays were
performed and concentrations of selected cytokines (IL-2,
TNF and IFN-g) were determined (Fig. 3).
In PBMCs, PMA and the costimulator PHA were used to
activate cytokine production. Sirolimus (0.25–1.0 nM) inhibited
PMA/PHA-activated cytokine production (IL-2 and TNF) in
PBMCs (Fig. 3). The sirolimus-induced downregulation of
IFN-g was not statistically significant, probably because of high
individual variations.
Additionally, cell proliferation after stimulation with
PHA was measured (data not shown). Sirolimus (0.25–1.0
nM) inhibited PHA-activated proliferation in PBMCs.
FIGURE 1. Time-course and dose–response of S6K1 phos-
phorylation after stimulation with PMA determined by West-
ern blot. The position of the 2 isoforms of phospho-S6K1,
phospho-p70 S6K (Thr389) and phospho-p85 S6K (Thr412),
are indicated. b-actin served as the loading control.
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The inhibitory effects of sirolimus on cell proliferation and
cytokine production were not influenced by dimethyl sulf-
oxide (DMSO), which was used as the solvent of siroli-
mus. These results confirmed the efficacy of sirolimus
treatment in vitro and demonstrated that reduction of phos-
pho-p70 S6K paralleled the reduction of proliferation and
immune competence of lymphocytes as indicated by the
IL-2, TNF, and IFN-g production. This observation sup-
ports the hypothesis that phosphorylated p70 S6K serves
as a promising biomarker of the effect of sirolimus on
mTOR.
A Novel p70 S6K ELISA Analysis Showed
a Dose-dependent Downregulation of
Phospho-p70 S6K by Sirolimus in
PMA-stimulated PBMCs
To quantitatively determine phospho-p70 S6K, the
concentrations were measured with a p70 S6K ELISA in the
FIGURE 3. Sirolimus inhibited PHA/PMA-activated cytokine
secretion of PBMCs. The supernatants were quantified for IL-2
(A), TNF (B), and IFN-g (C) by Human IL-2, TNF, and IFN-g ELISA.
Results were expressed as the percentage of the values in PHA/
PMA-activated sirolimus-untreated PBMCs (Control). Results from
PBMCs without stimulation were taken as basal value. Data were
presented as a mean 6 SD. Differences between quantitative
variables were analyzed by paired t test (*P , 0.05, versus
Control). Three independent experiments were performed.
FIGURE 2. Effect of sirolimus on phospho-S6K1 in PMA-
stimulated and unstimulated PBMCs determined by West-
ern blot. A, Western blot analysis. B and C, Densitometeric
analysis of Western blot results. Results were expressed by
density relative to b-actin and then normalized to basal
concentrations of phospho-p70 S6K (Thr389) and/or
phospho-p85 S6K (Thr412) in PBMCs. Results from a rep-
resentative buffy coat in PMA-stimulated cells (B, upper
part) and unstimulated cells (B, lower part) are shown. The
densitometeric analysis of 20 buffy coats are summarized as
a mean 6 SD in (C).
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same samples that had been previously analyzed by Western
blot (Fig. 4). The average concentrations of phospho-p70 S6K
were 3.09 U/100 mcg protein in unstimulated PBMCs, which
were increased to 12.39 U/100 mcg protein in PMA-stimulated
cells, respectively (buffy coats, n = 20). Similar to Western
blot, ELISA detected a dose-dependent depression of p70
S6K phosphorylation induced by sirolimus in PMA-stimulated
cells. The inhibition of phospho-p70 S6K detected by ELISA
was lower than that of phospho-p70 S6K detected by Western
blot; moreover, the inhibition was more similar to that of
phospho-S6 K1 (phospho-p70 S6K plus phospho-p85 S6K)
detected by Western blot (data not shown).
Log-Linear Correlation Between the Relative
Phospho-p70 S6K Values From ELISA and the
Relative Densities From Western Blot Analysis
Was Significant
To study the correlation between ELISA and Western
blot measurements, we compared relative values of phospho-
p70 S6K (normalized to basal concentrations) obtained from
ELISA with relative densities of phospho-p70 S6K (variation
of basal) obtained from Western blot by bivariate Spearman
rank correlation analysis. The semi-log scatter plot is shown in
Figure 5A. The Spearman correlation coefficient was rs = 0.70.
Correlation was significant at the 0.01 level (2-tailed). These
results demonstrate a strong correlation between the phospho-
p70 S6K ELISA and Western blot phospho-p70 S6K measure-
ments, although the inhibition of phospho-p70 S6K detected
by ELISA was lower than that detected by Western blot.
The Stability of the ELISA-based System
Showed a Low Interassay Variation
To evaluate the stability of the whole system, a Jurkat
cell line was chosen as a control. Protein extracts from
PMA-stimulated (125 ng/mL for 30 minutes) Jurkat cells were
obtained from 8 independent experiments. The average
phospho-p70 S6K value was 9.25 U/100 mcg protein, and
coefficient of variation was marked with 23%, which repre-
sented the whole system variation except the interassay variation
between ELISAs. One cell lysate from PMA-stimulated PBMCs
isolated from one buffy coat was analyzed in 5 assays using
ELISA kits with 3 different lot numbers to determine precision
between assays. The interassay variation was 6.7%.
ELISA Confirmed Individual Variability of p70
S6K Phosphorylation Among 20 Buffy Coats
The variability of p70 S6K phosphorylation was evalu-
ated in 20 distinct buffy coats. Response of PBMCs to serial
concentrations of sirolimus (0–1 nM) after stimulation with
PMA (125 ng/mL) is shown (Fig. 5B). PMA elevated the
absolute concentrations of phospho-p70 S6K in all specimens;
moreover, sirolimus downregulated the concentrations of
phosphorylated kinase in a dose-dependent fashion in PMA-
stimulated cells. The downregulation of phospho-p70 S6K in
unstimulated PBMCs was not as evident as that in PMA-stim-
ulated cells. The similarity of the results among distinct
FIGURE 4. Effect of sirolimus on phospho-p70 S6K in PMA-
stimulated and unstimulated PBMCs determined by the ELISA-
based method. The absolute concentrations of phospho-p70
S6K were measured in the same samples analyzed by Western
blot. Results were expressed in units after normalization to 100
mcg total protein (U/100 mcg protein). Data shown were
from 20 buffy coats and presented as mean 6 SD. In PMA-
stimulated cells, differences between quantitative variables
were analyzed by 1-way analysis of variance test. *P , 0.05,
versus sirolimus-untreated PBMCs.
FIGURE 5. A, Spearman rank correlation analysis (rs = 0.70,
P = 0.01) between the relative phospho-p70 S6K values from
ELISA and the log-transformed relative densities from Western
blot analysis in PBMCs. PBMCs isolated from 20 individuals
were incubated with serial concentrations of sirolimus (0,
0.25, 0.5, 0.75, and 1.0 nM) alone or together with PMA (125
ng/mL). Two hundred data points are shown and the trend
line is indicated. B, Similar tendency in responses of PBMCs to
serial concentrations of sirolimus observed by the ELISA-based
method. The absolute values of phospho-p70 S6K from 20
buffy coats were summarized in the presence of PMA.
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individuals confirms that our procedure for PMA stimulation
and sirolimus treatment on PBMCs is stable and reproducible.
Nonetheless, we observed interindividual variabilities
of p70 S6K phosphorylation not only in PBMCs without any
treatment but also in PBMCs with PMA stimulation and/or
inhibition with sirolimus. The interindividual variability in
absolute values of phospho-p70 S6K in the absence of PMA
was between 31% and 50% and that in the presence of PMA
was between 25% and 31%. In PMA-stimulated PBMCs, we
further calculated the relative phospho-p70 S6K concen-
trations in sirolimus-treated cells to that in untreated cells
and assessed interindividual variability. Interestingly, the
interindividual variability was reduced to 15%–25%. Thus,
the relative phosphorylation concentrations among the indi-
vidual cells were more comparable than the absolute phos-
phorylation concentrations.
DISCUSSION
Pharmacodynamic monitoring has long been a main
objective to improve the use of immunosuppressive medica-
tion. P70 S6K is one of the best characterized downstream
effectors of mTOR8,9 and might reflect at best differential sen-
sitivity of the mTOR raptor complex 1 to inhibition by siroli-
mus.8,17,18 Measuring the phosphorylation status of p70 S6K
offers a possible method for pharmacodynamic monitoring of
mTOR proliferation inhibitor.12,13,19–23 In a previous study, we
demonstrated the clinical relevance of measurement of the p70
S6K phosphorylation status by Western blot.12 Our observation
that there is no correlation of sirolimus trough level and the p70
S6K phosphorylation status was confirmed in a subsequent
study.13 Furthermore, a distinct stimulation of the p70 S6K
phosphorylation status was necessary to obtain a more reliable
measurement. Although measurement of the specific phosphor-
ylation status of the p70 S6K at the Thr389 site in cell lysates is
challenging, it was our aim to establish an ELISA to facilitate
monitoring of mTOR inhibitor treatment.
Similar to the Western blot, the ELISA detected a dose-
dependent suppression of p70 S6K phosphorylation by
sirolimus in PMA-stimulated cells. The inhibition rate of
phospho-p70 S6K detected by ELISA was lower than that of
phospho-p70 S6K detected by Western blot. One explanation
for this finding is that both isoforms share the same antibody-
binding site. The larger isoform of S6Kl, the p85 S6K, is
uniquely distinct from the shorter isoform in which it
contains an amino-terminal 23-amino acid extension.11 Even
so, in our experiments, the effects of a dose-dependent down-
regulation from sirolimus treatment were not influenced by
phospho-p85 S6K (Thr 412) in PMA-stimulated cells
because the contribution of phospho-p70 S6K to the concen-
trations of phospho-S6K1 exceeded that from phospho-p85
S6K by far. In addition, a log-linear correlation was observed
between relative phospho-p70 S6K values from ELISA and
relative densities from the Western blot analysis.
Leogrande et al13 found that with Western blot analysis,
sirolimus (10 ng/mL, even higher than ours) did not modify
basal p70 S6K phosphorylation in control PBMCs; instead,
the mTOR inhibitor significantly downregulated insulin-
stimulated phosphorylation of p70 S6K in a dose-dependent
fashion. These findings and ours demonstrate that both
Western blot and ELISA-based method were not sensitive
enough to detect the downregulation by sirolimus of the basal
phospho-p70 S6K activity. The PMA stimulation in vitro
might mimic the activation of mTOR in vivo by a transplant
or a tumor, respectively. As well as the molecular effects,
a parallel functional impact of p70 S6K inhibition on the
cytokine production was detected, that is, a significant down-
regulation of IL-2 and TNF by sirolimus in a dose-dependent
fashion (Fig. 3).
The interindividual variability of basic p70 S6K phos-
phorylation in PBMCs measured by our ELISA-based method
was 31%. The result is similar to the interindividual variability in
healthy controls using immunoblot analysis (39%).13 Possible
explanations for the high interindividual variability are substan-
tial individual variations. Furthermore, the low absolute basal
concentration values of phosphorylation in PBMCs have a greater
variability because they are located in the very beginning of the
standard curve. Interindividual variability in PMA-treated cells
was between 25% and 31%. The substantial variation in stimu-
lated PBMCs observed among individuals emphasized the future
need to use each patient as his or her own control in the analysis
of pharmacodynamic markers.
We presume that PMA-stimulated cells corresponded to
the original state of basal activation. The phosphorylation
ratio indicates phosphorylation relative to PMA-stimulated
cells. The phosphorylation ratio was downregulated when
sirolimus concentration increased. Under the same sirolimus
concentration, the buffy coat from different individuals had
different p70 S6K phosphorylation ratios. Previously, the
same phenomenon was observed.12,13 Clinically, patients with
similar sirolimus trough levels may show different clinical
outcomes. This finding implies that some patients with the
same sirolimus blood levels develop relevant rejection epi-
sodes as a consequence of insufficient suppression of p70
S6K phosphorylation, whereas others have serious adverse
events due to oversuppression. Our results have shown that
the ELISA technique enables the use of phospho-p70 S6K in
PBMCs as a biomarker of mTOR.
We are aware of the principal limitations of our system:
(1) First of all, the conclusions drawn from our cell culture
system have to be translated and further evaluated in the
clinical setting. A cell culture system, although consisting of
PBMCs from individual donors, cannot be able to mimic in
every respect the complex clinical situation after transplanta-
tion. For example, here we constantly measured cytokine
production after an incubation period of 72 hours, and also we
are aware that, for example, IL-2 production by CD4-positive
T cells in vivo is more rapid. (2) Furthermore, even though
ELISA needs less blood than Western blot, the amount is still
more than that needed for trough concentration measurement.
This might be a problem with frequent testing in anemic
patients. (3) Although the assay is easier to perform than
Western blot, the whole ELISA-based system is a multistep
procedure including PBMCs isolation, activation of cells with
PMA, cell lysis, protein concentration assay, and performing
the ELISA itself. Failing in any step will affect accuracy. (4)
Moreover, to calculate the phosphorylation ratio (percentage
of state without sirolimus), it is necessary to obtain blood from
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patients before sirolimus administration and to activate cells
in vitro with PMA. Then, after starting sirolimus therapy,
this procedure has to be repeated to evaluate the p70 S6K
phosphorylation response to sirolimus.
The utility of ELISA methodology extends well beyond
transplant immunosuppression. Further clinical applications are
oncology medicine and treatment of renal and cerebral tumors in
tuberous sclerosis. Conferring a proliferative advantage, the sir-
olimus-sensitive signal transduction pathway is a potential target
for cancer therapy in several types of neoplasms. Consequently,
the definition of a recommended dose range associated with
optimal biological activity is an important challenge. Different
approaches have been undertaken to establish a biochemical
monitoring of mTOR inhibition, especially in the field of
antitumor therapy.19–22 Overactivation of basal p70 S6K in
PBMCs from kidney transplant recipients was associated with
the presence of Kaposi sarcoma dermal lesions; conversely,
kinase inhibition was linked to regression of skin cancer le-
sions.23 Thus, monitoring of the p70 S6K phosphorylation status
in PBMCs might help to predict and monitor the biological
effectiveness of sirolimus in patients with Kaposi sarcoma and
potentially other carcinoma and might help to adjust the biolog-
ically appropriate mTOR inhibitor doses.
Recently, the technique of phospho-flow cytometry has
been validated for the detection of an mTOR-signaling–specific
pharmacodynamic biomarker in peripheral human blood.24 In
addition, the feasibility of real-time, direct pharmacodynamic
monitoring by flow cytometry was demonstrated during clinical
trials combining intensive chemotherapy and signal transduc-
tion inhibitors,25 but further validation in patients after solid
organ transplantation is urgently needed.
In summary, we successfully established an ELISA-
based method to investigate the immunosuppressive prop-
erties of sirolimus by assessing the phosphorylation status
of p70 S6K. Although this method needs activation of the
cells by PMA and the results may be influenced by p85 S6K
phosphorylated at its analogous sites, the dose-dependent
downregulation effect of sirolimus on the phosphorylated
kinase was not altered by PMA or p85 S6K. Future large-
scale studies now have to translate this technique into
clinical practice and should determine the phospho-p70
S6K interindividual and intrasubject variability over time,
the effect of interaction between mTOR inhibitors and
other immunosuppressive drugs, and the target value of
the phosphorylation ratio in renal transplant recipients.
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